Why the study?
Does sirolimus improve renal ischemia/reperfusion injury in normotensive and hypertensive rats?
Does sirolimus improve renal ischemia/reperfusion injury in normotensive and hypertensive rats?
Sirolimus ameliorates renal ischemia/reperfusion injury in normotensive rats but has limited long-term protective effects in the presence of severe high-renin hypertension.
Sirolimus benefits appear hypertension-dependent; leaves open mTOR inhibition efficacy in hypertensive transplant recipients.
Background. Renal ischaemia/reperfusion (I/R) injury and hypertension represent major alloantigen-independent factors contributing to the development of chronic allograft nephropathy of renal allografts. In the present study, we investigated the effect of the antiproliferative immunosuppressant, sirolimus (SIR), in a model of accelerated renal injury in hypertensive transgenic rats (TGRs). Twenty anaesthetized uninephrectomized TGRs with renin overproduction [TGR(mREN2)27] and 20 normotensive Han SD (SD) rats as genetic controls had their renal pedicles clipped for 45 min and were subsequently treated with either SIR (0.5 mg/kg per day, orally) or placebo (n= 10 in each group) for 16 weeks, after which time the kidneys were harvested for morphological and immunohistochemical analysis. High-renin hypertension aggravated the functional and structural changes induced by I/R in SD animals: both SIR-treated and untreated TGRs exhibited significantly greater proteinuria and suffered from more severe glomerulosclerosis (P < 0.01) and vasculopathy (P < 0.01), as well as compensatory renal hypertrophy (P < 0.01) and tissue TGF-β1 expression, than both normotensive SD groups (P < 0.01). SIR-treated SD rats showed reduced proteinuria (P < 0.01), glomerulosclerosis (P < 0.01), and TGF-β1 expression in the glomerular epithelium and proximal tubuli (P < 0.05) compared with placebo-treated SD rats. SIR-treated TGRs had significantly lower proteinuria at week 4 after I/R (P < 0.01) than placebo-treated TGRs, but there were no significant differences thereafter. Morphological patterns were similar in treated and untreated TGRs at week 16. High-renin-induced hypertension aggravated the renal injury induced by I/R. Sirolimus treatment ameliorated some late functional and morphological changes induced by I/R injury in hypertensive TGRs but, particularly, in normotensive SD rats.
No takes yet. Share an insight, caveat, or question.
Viklický et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: